A
Angela Botticella
Researcher at Institut Gustave Roussy
Publications - 34
Citations - 513
Angela Botticella is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Radiation therapy & Lung cancer. The author has an hindex of 7, co-authored 33 publications receiving 278 citations. Previous affiliations of Angela Botticella include Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Lizza E.L. Hendriks,Lizza E.L. Hendriks,Clemence Henon,Edouard Auclin,Laura Mezquita,Roberto Ferrara,Clarisse Audigier-Valette,Julien Mazieres,Corentin Lefebvre,Audrey Rabeau,Sylvestre Le Moulec,Sophie Cousin,Boris Duchemann,Cécile Le Péchoux,Angela Botticella,Samy Ammari,Anas Gazzah,Anas Gazzah,Caroline Caramella,Julien Adam,Emmanuèle Lechapt,David Planchard,Dirk De Ruysscher,Anne-Marie C. Dingemans,Benjamin Besse,Benjamin Besse +25 more
TL;DR: In multivariate analysis BMs are not associated with a poorer survival in patients with ICI-treated NSCLC, and stable patients with BM without baseline corticosteroids and a good ds-GPA classification have the best prognosis.
Journal ArticleDOI
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
Romain-David Seban,Laura Mezquita,Arnaud Berenbaum,Laurent Dercle,Angela Botticella,Cécile Le Péchoux,Caroline Caramella,Eric Deutsch,Serena Grimaldi,Julien Adam,Samy Ammari,David Planchard,Sophie Leboulleux,Benjamin Besse +13 more
TL;DR: Baseline tumor burden (TMTV) on FDG PET/CT scans and inflammatory status (dNLR) were associated with poor OS and absence of DCB for ICI treatment in advanced NSCLC patients, unlike tumor SUVmax, and may be used together to improve the selection of appropriate candidates.
Journal ArticleDOI
Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment
Elie El Rassy,Angela Botticella,Joseph Kattan,Cécile Le Péchoux,Benjamin Besse,Lizza E.L. Hendriks,Lizza E.L. Hendriks +6 more
TL;DR: The preclinical rationale and potential concerns for the use of ICI in BM patients are summarized, and cranial objective response rate (ORR) was comparable to extracranial ORR and responses were often durable.
Journal ArticleDOI
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
Lizza E.L. Hendriks,Lizza E.L. Hendriks,Gerben Bootsma,Jean Mourlanette,Clemence Henon,Laura Mezquita,Roberto Ferrara,Clarisse Audigier-Valette,Julien Mazieres,Corentin Lefebvre,Boris Duchemann,Sophie Cousin,Cécile Le Péchoux,Angela Botticella,Dirk De Ruysscher,Anne-Marie C. Dingemans,Benjamin Besse,Benjamin Besse +17 more
TL;DR: Some patients with NSCLC having LM do benefit from ICI treatment; specifically, those in the NCCN LM good prognosis group can obtain a long survival.
Journal ArticleDOI
Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.
Antoine Schernberg,Laura Mezquita,A. Boros,Angela Botticella,Caroline Caramella,Benjamin Besse,Alexandre Escande,David Planchard,Cécile Le Péchoux,Eric Deutsch +9 more
TL;DR: In stage III NSCLC patients, treated with concurrent cisplatin-based chemoradiation, baseline leukocytosis and neutrophilia were associated with worse OS, PFS, LRC, and DMC, and this independent cost-effective biomarker could help to stratify stage IIINSCLC population with more accuracy.